To compare elevated intraocular pressure (IOP) management and outcomes among patients with diabetic macular edema who received fluocinolone acetonide (FAc) implants versus sham-control treatment and explore the prior ocular steroid exposure impact on IOP outcomes.
INTRODUCTION
Phase 3 clinical trials of vascular endothelial growth factor (VEGF) inhibitors in patients with diabetic macular edema (DME) have led to their U.S. Food and Drug Administration (FDA) approval and a paradigm shift in DME treatment strategies. [1] [2] [3] [4] [5] However, despite visual acuity improvement in many patients receiving anti-VEGF therapies, an appreciable number experience suboptimal results, even with monthly treatment. 4, 6 It is becoming apparent that multiple inflammatory and angiogenic factors, in addition to VEGF, contribute to DME pathogenesis and can be reduced by corticosteroids. 7, 8 Two phase 3 clinical trials investigating intravitreal corticosteroid-releasing implants for patients with DME -FAME (fluocinolone acetonide [FAc] [Iluvien 0.2 µg/day FAc; Alimera Sciences, Alpharetta, GA]) and MEAD (dexamethasone [Ozurdex; Allergan, Irvine, CA]) -met their primary endpoints of percentage of patients gaining 15 or more letters in best-corrected visual acuity (BCVA) compared with sham control treatment at 2 and 3 years post-baseline, respectively. 9, 10 The FAME trials also demonstrated significant visual acuity improvement 3 years from baseline, with the majority of patients requiring only one implant during the 3-year study. 11 These intravitreal steroid formulations are FDA-approved for treating patients with DME. 12, 13 Corticosteroids represent a treatment option for certain patients with DME; however, class-specific adverse events must be considered before treatment initiation. [14] [15] [16] [17] [18] Approximately 40% of intravitreal corticosteroid-treated patients develop elevated intraocular pressure (IOP), a risk factor for glaucoma development. [18] [19] [20] However, elevated IOP following intravitreal corticosteroid treatment may not necessarily indicate glaucomatous change (Parrish RK, also in this issue).
Iluvien (0.2 µg/day FAc) is approved by the FDA for the treatment of DME in patients who have previously been exposed to a course of corticosteroids but did not have a clinically significant rise in IOP. 13 Because this is how 0.2 µg/day FAc will be used clinically in the United States, the present analysis will examine IOP treatment and outcomes in the FAME trials and compare patients who received a prior course of intravitreal corticosteroids with those who did not.
PATIENTS AND METHODS
Details of the FAME trials have been described previously. 10 Briefly, the FAME trials compared two doses of FAc (0.2 µg/day and 0.5 µg/day) with sham control in patients with DME. The FDA-approved dose for Iluvien is 0.2 µg/day FAc; however, the 0.5 µg/day FAc-treated patient cohort was included to investigate dose-related effects. 13 Importantly, patients treated with corticosteroid prior to enrollment in the FAME trials were excluded if they experienced an uncontrolled rise in IOP. The goal of the current analysis was to investigate IOP management strategies and the effect of these interventions on vision outcomes, as well as to explore the impact of prior ocular steroid exposure on IOP outcomes among patients from the FAME trials. The FAME trials adhered to the tenets of the Declaration of Helsinki. The study protocol and patient consent form were approved by each institution's governing institutional review board or ethics committee. The trials complied with the rules and regulations provided by the Health Insurance Portability and Accountability Act of 1996. All patients provided written informed consent. These trials are registered at www.clinicaltrials.gov (NCT00344968).
Clinical Assessments
Study assessments included IOP measured by Goldmann applanation tonometry (at screening and each post-treatment visit), as well as need for concomitant medications and procedures. The average of three measurements taken using the investigator's standard procedure was computed. BCVA was measured using Early Treatment Diabetic Retinopathy Study charts at 4 m or electronic visual acuity testers at 3 m.
Management of IOP During the FAME Trials
As stipulated in the protocol, topical medications were first-line IOP-lowering treatments. It was recommended that treatment be initiated when IOP was greater than 30 mm Hg, but it could be started at a lower level at the treating investigator's discretion. If IOP was between 22 mm Hg and 30 mm Hg, it was remeasured within 1 month; IOP greater than 25 mm Hg at consecutive quarterly visits was treated. The trials were monitored by a data safety monitoring committee, which included a glaucoma expert (RKP). This group reviewed unmasked data every 6 months and made recommendations regarding study design changes and continuation, including changes to the quarterly visit schedule. During the 36 months of follow-up, no changes were recommended.
Detailed Analysis of IOP Elevations Occurring During the FAME Trials
Development and management of IOP-related events after FAc implant receipt during the FAME trials are characterized herein. This report examines differences between patients based on ocular corticosteroid treatment prior to enrollment in the FAME trials to determine the predictive clinical value of steroid exposure. Investigators entered data at randomization regarding prior ocular steroid injection, which required source documentation.
Statistical Methods for the Detailed Analysis
The population included all randomized patients receiving any study drug. Categorical data were sum- marized using counts and percentages and were analyzed using either Pearson's chi-square test or Fisher's exact test, as appropriate. No data imputation for missing values was used, and no adjustments to type 1 error rate were made to account for multiple comparisons.
RESULTS

Description of Patients
A total of 953 patients, randomized to receive either sham control (n = 185), 0.2 µg/day FAc (n = 375), or 0.5 µg/day FAc (n = 393), were included in this subanalysis. Prior ocular steroid injection was received by 36 patients from the sham control (19.8%), 72 patients from the 0.2 µg/day FAc (19.7%), and 76 patients from the 0.5 µg/day FAc (19.6%) groups. Overall, baseline characteristics were balanced regardless of prior steroid injection (Table 1) ; however, a few exceptions were noted. There was a greater percentage of phakic patients among those who received no prior steroid than among those who received prior steroid. Among Asian patients who received sham control or 0.2 µg/day FAc treatment, a greater percentage did not receive prior steroid than received prior steroid.
Incidence of Elevated IOP in the FAME Trials
In the overall population, IOP elevations greater than 30 mm Hg were more common in patients receiving either FAc dose versus sham control, with IOP elevations occurring more frequently in patients receiving 0.5 µg/day FAc versus 0.2 µg/day FAc ( Table 2 ). Among those with prior steroid exposure, there was a numerically, but not significantly, greater percentage of patients who experienced IOP elevations greater than 30 mm Hg in the FAc versus sham-control arms. Among those without prior steroid exposure, a significantly greater percentage of FAc-versus sham control-treated patients experienced an IOP elevation greater than 30 mm Hg.
IOP-Lowering Medications
In the overall population, medication was used more frequently to lower IOP than trabeculoplasty or surgery (Table 3) . Medication use was more common in patients who received either FAc dose compared with sham control. In general, medication use effectively lowered IOP (Table 4) . Among patients treated with 0.2 µg/day FAc who received IOP-lowering medication and had two or more postintervention IOP assessments, seven of 108 (6.5%) had IOP levels that remained 30 mm Hg or higher following intervention. Of these seven patients, three did not receive an intravitreal corticosteroid prior to enrollment in the FAME trials. Of the four remaining patients, two were treated during the FAME trials (one patient, who was receiving IOPlowering medication at randomization, received six intravitreal steroid treatments between months 12 . Across the three study arms, a numerically greater incidence of medication use was observed in patients who received prior ocular steroid than in those who did not ( Table 5 ). The majority of patients requiring medication after receiving a 0.2 µg/day FAc implant did so within the first year (61.1% of the full population; 66.6% of patients who received only one implant during the 3-year study).
Trabeculoplasty
For patients whose elevated IOP did not respond to medication, laser trabeculoplasty was an effective treatment option. In the overall population, 14 patients (four and 10 patients in the 0.2 µg/day and 0.5 µg/day FAc arms, respectively) underwent trabeculoplasty (Table 3) . Trabeculoplasty was performed only on FAc-treated patients and, among those patients, elevated IOP was generally reduced following the procedure (Table 4) . Overall, of the 14 patients treated with laser trabeculoplasty, nine (64.3%) did not require surgery (Table 6) . Of the four patients treated with 0.2 µg/ day FAc who underwent trabeculoplasty, one required subsequent IOP-lowering surgery (Table 6 ).
Incisional Surgery
In the overall population, a greater percentage of FAc-treated patients than sham control-treated patients required IOP-lowering surgery, and this was dose dependent (Table 3) . Surgical intervention largely reduced elevated IOP levels regardless of study arm (Table 4) .
Among the 72 patients treated with 0.2 µg/day FAc who received prior ocular steroid treatment, none required surgery; however, of the 294 patients treated with 0.2 µg/ day FAc who did not receive prior ocular steroid treatment, 18 required surgery (0% vs. 6.1%; P = .030) ( Table 7) .
Visual Outcomes Following IOP Elevations
Patients in the 0.2 µg/day FAc arm achieved similar visual acuity outcomes at month 36 regardless of whether IOP-lowering interventions were used (Figure 1) . Specifically, similar proportions of patients achieved a BCVA of 20/40 or higher in the groups requiring medication or surgery compared with those who did not require intervention ( Figure  1, left panel) . Furthermore, the proportions of patients achieving a 15-lettter or greater improvement in BCVA from baseline were similar among the three intervention groups (Figure 1, right panel) .
The IOP and BCVA outcomes for the 0.2 µg/day FAc-treated patient who had the highest increase in vertical cup-to-disc ratio among FAME trial participants are shown in Figure 2 . Visual acuity improvements for this patient were maintained throughout the study, and elevated IOP was treated with medication and trabeculoplasty; ultimately, the patient underwent IOP-lowering surgery at month 33. Of note, this patient did not receive prior ocular corticosteroid treatment.
DISCUSSION
This subanalysis describes the occurrence and management of elevated IOP based on prior ocular corticosteroid treatment and provides information regarding outcomes after IOP-lowering treatment. These findings contribute to the understanding of the overall benefit-risk ratio of the FAc implant. Consistent with known intravitreal corticosteroid class effects, [14] [15] [16] [17] [18] elevated IOP occurred more frequently in FAc-than sham control-treated patients. Similarly, more FAc-treated patients required IOPlowering interventions. However, no patient who received 0.2 µg/day FAc and was treated previously with an ocular steroid required IOP-lowering surgery. Similar proportions of patients achieved a 20/40 or better visual outcome regardless of IOPlowering intervention, which is meaningful given that 20/40 or better vision is required for driving. 21 The Iluvien (0.2 µg/day FAc) FDA indication is unique among pharmacotherapies for the treatment of DME in that it stipulates that patients must have been treated with a prior course of corticosteroid without experiencing a clinically significant rise in IOP. 1, 2, 12, 13 This stipulation is meant to mitigate the risk of elevated IOP associated with Iluvien (0.2 µg/ day FAc) and is supported by the current analysis. These findings are consistent with a retrospective analysis of IOP response to intravitreal triamcinolone acetonide (IVTA) based on prior steroid exposure (prednisolone), which reported that no patient who received prior topical steroid required surgical intervention following IVTA treatment. 22 In the FAME trials, topical medication was the most frequently used IOP management intervention, and it effectively reduced IOP elevations. Among 0.2 µg/day FAc-treated patients, IOP-lowering medication was used more frequently in patients who were previously treated with an ocular steroid than in those who were not. Patients with a history of uncontrolled IOP elevation unresponsive to topical therapy were excluded from the FAME trials. 10 Thus, IOP elevations in patients who were previously treated with an ocular steroid were, by definition, managed successfully prior to entry into the FAME trials and, therefore, may have been Overall, medication generally reduced elevated IOP; however, in some cases, trabeculoplasty or surgery was necessary. When required, surgery effectively reduced elevated IOP. Whether a continuously releasing steroid implant contributed to surgical success due to the known antifibrotic corticosteroid effects is unknown, but it is a hypothesis that should be further investigated.
As shown by these analyses, patients treated with 0.2 µg/day FAc who (1) had prior ocular steroid exposure and (2) met the exclusion criteria of not having an uncontrolled IOP elevation that did not respond to topical IOP-lowering therapy did not require IOP-lowering surgery (despite being enrolled across multiple sites in which treatment decisions were independently made by multiple physicians). These results were the basis for the FDA indication requiring a prior course of corticosteroid without a clinically significant rise in IOP; this mitigates the risk of elevated IOP to a degree that results in a positive benefit-risk ratio for 0.2 µg/day FAc in treating DME.
Based on the observed success of trabeculoplasty in this albeit limited number of patients treated with the FAc implant, a working algorithm for managing 0.2 µg/day FAc-associated IOP elevations may be to initiate topical therapy intervention, then proceed to trabeculoplasty if necessary. BCVA and IOP during a 36-month period for the patient treated with 0.2 µg/day FAc who had the highest vertical cup-to-disc increase in the FAME trials. This patient had a cup-to-disc increase of 0.45 and at month 24, an adverse event of nerve fiber layer hemorrhage was reported (at the same time, increased cupping was noted by the investigator). Note: red lines represent IOP-lowering medicaton. BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; FAc = fluocinolone acetonide; IOP = intraocular pressure; R = retreatment; S = IOP-lowering surgery; T = trabeculoplasty.
If trabeculoplasty proves inadequate, surgery may be required. These results suggest a minimal risk of developing elevated IOP that is unresponsive to noninvasive interventions in patients who satisfy the FDA indication. Moreover, when surgery was deemed necessary, the risk of glaucomatous change to the optic nerve head was minimal.
The data from the FAME trials do not allow for correlations to be made between elevated IOP associated with a prior course of corticosteroid and that associated with 0.2 µg/day FAc. These data will come from future postmarketing studies, as well as from clinical experience. To date, more than 2,000 FAc implants have been administered in the European Union, and only two IOP-lowering surgeries have been reported.
Given the similar glucocorticoid receptor binding affinity of FAc, triamcinolone acetonide, and dexamethasone, 23 it is reasonable to speculate that these agents may be predictive of IOP response for each other. The 0.2 µg/day FAc FDA indication does not stipulate a route of administration for the prior course of corticosteroid. 13 Therefore, the prednisolone challenge as a predictor of IOP response to IVTA is relevant for physician identification of eligible patients for treatment with 0.2 µg/ day FAc. The data presented herein and the exclusion criteria for the FAME trials collectively support the prior corticosteroid challenge and provide a mechanism for clinicians prescribing 0.2 µg/day FAc for DME to maximize the benefit-risk ratio. 
